EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations

Andrea Necchi iD, Rodryg Ramlau, Alejandro Falcón González, Arvind Chaudhry, Tilman Todenhöfer, Rana Tahbaz, Elisa Fontana, Patrizia Giannatempo, Jean-Laurent Deville, Damien Pouessel, Shinkyo Yoon, Thomas Powles und 10 weitere

JNCI Cancer Spectrum · 2024

DOI: 10.1093/jncics/pkae030 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JNCI Cancer Spectrum, 2024. Verfasst von Andrea Necchi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Receptor, Fibroblast Growth Factor, Type 3. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Basilea Pharmaceutica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This Phase 1b/2 study assessed the efficacy in terms of objective response rate (ORR) of the FGFR1/2/3 kinase inhibitor derazantinib as monotherapy or in combination with atezolizumab in patients with metastatic urothelial cancer (mUC) and FGFR1-3 genetic aberrations (FGFR1-3GA).

Methods

This multicenter, open-label study comprised 5 substudies. In Substudies 1 and 5, patients with mUC with FGFR1–3GA received derazantinib monotherapy (300 mg QD in Substudy 1, 200 mg BID in Substudy 5). In Substudy 2, patients with any solid tumor received atezolizumab 1200 mg every 3 weeks plus derazantinib 200 or 300 mg QD. In Substudy 3, patients with mUC harboring FGFR1–3GA received derazantinib 200 mg BID plus atezolizumab 1200 mg every 3 weeks. In Substudy 4, patients with FGFR inhibitor-resistant mUC harboring FGFR1–3GA received derazantinib 300 mg QD monotherapy or derazantinib 300 mg QD plus atezolizumab 1200 mg every 3 weeks.

Results

The ORR for Substudies 1 and 5 combined was 4/49 (8.2%, 95% confidence interval = 2.3% to 19.6%), which was based on 4 partial responses. The ORR in Substudy 4 was 1/7 (14.3%, 95% confidence interval = 0.4% to 57.9%; 1 partial response for derazantinib 300 mg monotherapy, zero for derazantinib 300 mg plus atezolizumab 1200 mg). In Substudy 2, derazantinib 300 mg plus atezolizumab 1200 mg was identified as a recommended dose for Phase 2. Only 2 patients entered Substudy 3.

Conclusions

Derazantinib as monotherapy or in combination with atezolizumab was well-tolerated but did not show sufficient efficacy to warrant further development in mUC. Clinicaltrials.gov NCT04045613, EudraCT 2019-000359-15

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsReceptor, Fibroblast Growth Factor, Type 3HumansMaleFemaleAgedMiddle AgedReceptor, Fibroblast Growth Factor, Type 1Aged, 80 and overReceptor, Fibroblast Growth Factor, Type 2Urinary Bladder NeoplasmsUrologic NeoplasmsAdultProtein Kinase InhibitorsCarcinoma, Transitional Cell

Substanzen

Antibodies, Monoclonal, HumanizedatezolizumabReceptor, Fibroblast Growth Factor, Type 3FGFR3 protein, humanReceptor, Fibroblast Growth Factor, Type 1FGFR1 protein, humanReceptor, Fibroblast Growth Factor, Type 2Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy.
  • Vita-Salute San Raffaele University, Milan, Italy.
  • Oncology Department, Poznań University of Medical Sciences, Poznań, Poland.
  • Department of Medical Oncology, Hospital Universitario Virgen Del Rocio, Sevilla, Spain.
  • Medical Oncology Associates, Summit Cancer Centers, Spokane, WA, USA.
  • Studienpraxis Urologie, Nürtingen, Germany.

ORCID-Profile: Andrea Necchi, Marc Engelhardt

Förderung

  • Basilea Pharmaceutica

Zitieren

APA

Necchi, A., Ramlau, R., Falcón González, A., Chaudhry, A., Todenhöfer, T., Tahbaz, R., Fontana, E., Giannatempo, P., Deville, J. L., Pouessel, D., Yoon, S., Powles, T., Bernat, M., Häckl, M., Marszewska, M., McKernan, P., Saulay, M., Scaleia, F., Engelhardt, M., …, & De Santis, M. (2024). Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae030

Vancouver

Necchi A, Ramlau R, Falcón González A, Chaudhry A, Todenhöfer T, Tahbaz R, et al. Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations. JNCI Cancer Spectrum. 2024. doi:10.1093/jncics/pkae030

BibTeX
@article{Necchi2024,
  author = {Necchi, Andrea and Ramlau, Rodryg and Falcón González, Alejandro and Chaudhry, Arvind and Todenhöfer, Tilman and Tahbaz, Rana and Fontana, Elisa and Giannatempo, Patrizia and Deville, Jean-Laurent and Pouessel, Damien and Yoon, Shinkyo and Powles, Thomas and Bernat, Mathieu and Häckl, Manuel and Marszewska, Michalina and McKernan, Phil and Saulay, Mikael and Scaleia, Federica and Engelhardt, Marc and Loriot, Yohann and Siefker-Radtke, Arlene and De Santis, Maria},
  title = {Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations},
  journal = {JNCI Cancer Spectrum},
  year = {2024},
  doi = {10.1093/jncics/pkae030}
}
Kostenlos starten →